Original research / Quantum Health

Quantum Healthcare’s Smaller Loss Has Yet to Translate Into Dividend Capacity

Quantum Healthcare narrowed its nine-month loss, but operating cash inflow fell to S$74,000 and the group remained in a working-capital deficit. It declared no dividend, citing accumulated losses.

Dividends.sg ·

Quantum Healthcare Limited (SGX: V8Y) reported a smaller loss for the nine months ended 30 September 2026. For shareholders looking for a dividend, the more pressing question is whether that improvement is turning into cash. Its 11 November results show that operating cash inflow fell sharply, while the group declared no dividend because of accumulated losses. The figures are unaudited. [S1, p. 3] [S1, p. 8] [S1, p. 23] [S1, p. 26] [S1, p. 29]

A smaller loss, but little operating cash

Nine-month revenue rose to S$9.875 million from S$9.599 million. The loss attributable to owners of the company narrowed to S$461,000 from S$686,000. The healthcare segment made a S$164,000 profit before tax, but the corporate segment lost S$482,000, leaving the group with an overall loss before tax. Better clinic performance has therefore not yet produced a group profit for ordinary shareholders. [S1, p. 3] [S1, p. 13] [S1, p. 23]

Net cash generated from operating activities was S$74,000, down from S$1.665 million in the comparable nine months of 2025, a decline of about 96%. The cash-flow statement shows an S$895,000 increase in trade and other receivables as a use of cash. Management says this movement mainly reflected a S$600,000 short-term advance to Aios Bio Sciences. This helps explain the weak reported cash inflow, but it does not make the period’s cash generation comparable with last year’s. [S1, p. 8] [S1, p. 25]

The filing says Aios Bio repaid the S$600,000 principal, together with S$22,882.19 of accrued interest, on 16 October 2026. That is a useful development after the September balance-sheet date. It does not change the S$74,000 operating cash figure reported for the nine-month period or establish the group’s later cash balance. [S1, p. 10] [S1, p. 28]

Liquidity still comes first

At 30 September, Quantum held S$1.219 million in cash, down from S$2.708 million at the end of 2025. Current liabilities of S$9.109 million exceeded current assets of S$4.526 million. The filing identifies a S$4.583 million working-capital deficit and S$1.426 million of negative group equity, and says these conditions create material uncertainty about the group’s ability to continue as a going concern. [S1, p. 4] [S1, p. 10]

The group also had S$856,000 of secured borrowings repayable within one year or on demand at the reporting date. Management points to cash from its healthcare operations, the Aios repayment and support over certain amounts owed to a former chief executive among its reasons for using the going-concern basis. Those are management’s stated considerations; the filing says they depend on uncertain future events. Its FY2025 auditors issued a disclaimer of opinion. [S1, p. 10] [S1, p. 11] [S1, p. 19] [S1, p. 23]

What would change the dividend picture?

Quantum explicitly said it had neither declared nor recommended a dividend for the reporting period because the group had accumulated losses. The smaller loss is progress, but the reported cash inflow and balance sheet give shareholders little basis to treat a payout as imminent. The next results should show whether clinic earnings can support stronger cash generation after working-capital movements, and whether the liquidity deficit narrows. [S1, p. 3] [S1, p. 8] [S1, p. 10] [S1, p. 26]